Dr. Gill has 40 years of strategic management, research, and technology commercialization experience in the life sciences industry. As the Launchpad Venture Group P&CEO of TruTouch, in raising $9.2M of $13.5M in order to develop & commercialize the TT2500 & TTAS6000 & bring the 7 year old “Alcohol & Biometric” Company back to the Workplace market in less than 4 years. As President and Chief Executive Officer of ProNAi Therapeutics, the Kalamazoo, MI, based DNAi Drug Development Company for which he & his team raised $11.5M of $13M invested in achieving an IND APPROVED lead drug product PNT2258, in less than 2 year from the pre IND briefing meeting with the FDA, & previously as President and Chief Executive Officer of Signet Laboratories the Dedham, MA, based Evidence Based Medicine company, for which he led a successful M&A strategy – sold to Covance, and prior to that Dr. Gill was the President and Chief Executive Officer of AnVil, the Burlington, MA, based preeminent commercialization partner to the life sciences industry focused on in silico drug discovery and drug development solutions.
Prior to AnVil Dr.Gill served as President and Chief Executive Officer of ActiveCyte, Newton, MA, which provided an enterprise wide solution for pharmaceutical intellectual property licensing, & was sold to Wolter’s Kluwer. Dr. Gill served as President and Chief Operating Officer of Genome Therapeutics Corp; now Oscient Pharmaceuticals (NASDAQ: GENE now OSCI), a Waltham, MA, genomics company, which focuses on the commercialization of genomics-based drug discovery. He had overall operational and strategic management responsibilities and led the company’s successful follow on financing efforts raising $55M. Prior to this Dr. Gill served as General Manager and Senior Vice President of BTG International, Inc., a subsidiary of BTG plc (LSE: BGC), a global leader in the patenting, marketing, and commercialization of intellectual property rights. He led the global biosciences sector of this $1.5 billion company that commercializes technology via acquisition and licensing collaborations with pharmaceutical, biotechnology, and physical sciences companies. Dr. Gill helped lead the management buyout of British Technology Group plc from the British government, the firm’s expansion into international markets, and its subsequent initial public offering. Earlier, he held positions of increasing responsibility in research and general management with Unilever plc. in the United Kingdom. Dr. Gill holds a Ph.D. in Endocrinology and a B.Sc. with honors in Physiology and Biochemistry from Reading University, UK.